Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical utility of genetic variants of glutamate carboxypeptidase II in predicting breast cancer and prostate cancer risk.

Cancer genetics - 1 Nov 2015

Naushad Shaik Mohammad, Shree Divyya Parvathaneni, Janaki Ramaiah M, Alex Stanley Balraj, Prasanna Lakshmi S, Vishnupriya J, Kutala Vijay Kumar

Abstract excerpt

In view of documented evidence showing glutamate carboxypeptidase II (GCPII) inhibitors as promising anti-cancer agents, certain variants of GCPII modulate breast and prostate cancer risk, and we developed an artificial neural network (ANN) model of GCPII variants and ascertained the risk associated with eight genetic variants of GCPII. In parallel, an in silico model was developed to substantiate the ANN...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antigens, Surface

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Area Under Curve

Share to Breast Neoplasms

Share to Genetic Variation

Share to Models, Genetic

Share to Neural Networks, Computer

Share to Prostatic Neoplasms

Source

Identifiers

PMID: 26471812
DOI: 10.1016/j.cancergen.2015.09.001

Genes

FOLH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical utility of genetic variants of glutamate carboxypeptidase II in predicting breast cancer and prostate cancer risk.PMID 26471812Read ↗

Paradoxical role of C1561T glutamate carboxypeptidase II (GCPII) genetic polymorphism in altering disease susceptibility.Semantic proximity Read ↗

Glutamate Carboxypeptidase II: An Overview of Structural Studies and Their Importance for Structure-Based Drug Design and Deciphering the Reaction Mechanism of the EnzymeSemantic proximity Read ↗

Structural and biochemical characterization of the folyl‐poly‐γ‐<scp>l</scp>‐glutamate hydrolyzing activity of human glutamate carboxypeptidase <scp>II</scp>Semantic proximity Read ↗

Prediction of the Effect of Naturally Occurring Missense Mutations on Cellular <i>N-Acetyl-Glucosaminidase</i> Enzymatic ActivitySemantic proximity Read ↗

GCPII Variants, Paralogs and OrthologsSemantic proximity Read ↗

In silico approaches to identify the potential inhibitors of glutamate carboxypeptidase II (GCPII) for neuroprotection.Semantic proximity Read ↗

Glutamate carboxypeptidase II (GCPII) genetic variants as determinants of hyperhomocysteinemia: implications in stroke susceptibility.Semantic proximity Read ↗

Mapping of the active site of glutamate carboxypeptidase II by site‐directed mutagenesisSemantic proximity Read ↗

Relations of glutamate carboxypeptidase II (GCPII) polymorphisms to folate and homocysteine concentrations and to scores of cognition, anxiety, and depression in a homogeneous Norwegian population: the Hordaland Homocysteine Study.Semantic proximity Read ↗

Genetic Variation in Glutamate Carboxypeptidase II and Interaction with Dietary Natural Vitamin C May Predict Risk for Adenomatous Polyp Occurrence.Semantic proximity Read ↗

Genetic variation in folylpolyglutamate synthase and gamma-glutamyl hydrolase and plasma homocysteine levels in the Singapore Chinese Health Study.Semantic proximity Read ↗

GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.